INFO:
PILA PHARMA PUBLISHES THE ANNUAL REPORT 2024
The report in Swedish can be found here
Millionærklubben by EuroInvestor [14. November 2024]
CEO Gustav H. Gram participates in Denmark’s largest finance and investment podcast to elaborate on PILA PHARMA and discuss the emerging trends within the obesity and diabetes market.
Please, find the link to the video (in Danish) here
ARTICLES:
Obesity and diabetes are serious global health challenges.
In this interview with SVT (Swedish national public television broadcaster), Dorte shares her unique approach to tackling these issues—with the help of chili.
Watch and read the full article here to learn more about her vision and the science behind it (in Swedish).
2. analyse – Pila Pharma Halvårsrapport 2024 (September 30, 2024)
Read the report PDF (in Danish) here
Read the report (in Swedish) here
Read the report PDF (in Danish) here
Read the report (in English) here
PRESENTATIONS AND INTERVIEWS:
Fedmemarkedet handler primært om glp1, senere er amylin blevet kendt, men det dansk-svenske biotekselskab Pila Pharma, grundlagt af Dorte X. Gram med rødder i Novo Nordisk, udvikler en oral behandling mod type 2-diabetes og fedme baseret på en såkaldt chili-receptor. Hør mere i denne video, hvor Helge Larsen har besøg af Dorte X. Gram.
Find the link to the video (In Danish) here
PILA PHARMA STOKK.io After-Work Q&A [October 28, 2024]
PILA PHARMA’s CEO, Mr. Gustav H. Gram hosts an investor after-work Q&A specifically tailored with investor questions collected from different Stock trading forums and PILA PHARMA’s social media platforms.
In this session he answers questions from investors that touches upon the status, happenings and other things such as the market and global trends for Diabetes, Obesity and Cardiovascular disease, disease areas that PILA aims to address.
The Q&A was held together with moderator Anders Egsvang Rasmussen from Stokk.io, a platform that facilitates investor reach for companies.
The Q&A is conducted in English here